Google Ven­tures’ Kr­ish­na Yesh­want is hunt­ing for the next big new idea in biotech

Kr­ish­na Yesh­want

Bill Maris brought in Kr­ish­na Yesh­want as a Google Ven­tures part­ner back in the ear­ly days of 2009. The Har­vard MD/MBA with a com­put­er sci­ences back­ground at Stan­ford and a track record of his own start­ing and sell­ing soft­ware com­pa­nies had that blend of ed­u­ca­tion, youth­ful ex­pe­ri­ence and cross-pol­li­nat­ing in­tel­lect Google want­ed to bring to its in­vest­ment group.

Maris is leav­ing now, but Yesh­want is stay­ing put, run­ning a cross-coun­try life sci­ences team that con­tin­ues to hunt out pre-fledg­ling in­vest­ments in biotech. Where most VCs in the biotech world op­er­ate with a very clear ex­it strat­e­gy — whether they’re go­ing for the long throw of a dis­tant IPO or a quick val­ue mak­er 12 months from the first mon­ey in — Yesh­want and his crew mem­bers are hap­py to play the long game, with­out keep­ing an eye on the clock.

They proved that with Yesh­want’s first in­vest­ment, when Google Ven­tures — now brand­ed sim­ply GV — backed Till­man Gern­gross’s an­ti­body pro­duc­tion shop Adimab, near Dart­mouth.

“In a big way, Till­man took a bet on us,” Yesh­want tells me of the then new­ly spawned ven­ture group and his own new ca­reer in VC.

Adimab wasn’t go­ing for the quick flip, an IPO or any kind of overnight suc­cess that would make Google sud­den­ly rich­er. But that wasn’t the point. Now val­ued at more than half a tril­lion dol­lars, the moth­er ship at the on­line search en­gine-turned-tech-con­glom­er­ate isn’t try­ing to im­press any­one with its abil­i­ty to pick win­ners. What it does want to do, through its ven­ture teams like the one Yesh­want leads, is back peo­ple work­ing on ideas that can of­fer a last­ing, re­al im­pact on so­ci­ety.

For most VCs, that might sound a tri­fle glib. Google’s track record, though, backs it up.

Yesh­want is the po­lar op­po­site of a late-stage in­vestor. He and his team like to get start­ed dis­cussing com­pa­nies while they are still in the idea stage. Big ideas in in­fec­tious dis­eases (and where it blends in­to can­cer R&D), di­ag­nos­tics, rheuma­tol­ogy (which over­laps with their im­munol­o­gy work) as well as the whole pay­er/provider uni­verse are top of mind these days. Im­muno-on­col­o­gy, which has been ex­plod­ing with new re­search pacts this year, is still just scratch­ing the sur­face of its po­ten­tial, says Yesh­want.

Yesh­want’s ex­it strat­e­gy: “We think of it dif­fer­ent­ly,” he says, gaug­ing suc­cess by the “im­pact on the pa­tient.” Ex­its are on the back burn­er. Mak­ing new en­trances and tack­ling big ideas, that’s what at­tracts the at­ten­tion of Google’s ven­ture play­ers.

Google’s ven­ture group is by no means de­vot­ed en­tire­ly to life sci­ences, but it has made the high risk/high re­ward in­dus­try its biggest sin­gle fo­cus. Adimab has been fol­lowed by a string of biotech in­vest­ments in com­pa­nies like Forty Sev­en, an on­col­o­gy start­up that re­cent­ly sprang out of the lab of Stan­ford’s Irv Weiss­man with a re­mark­ably ad­vanced plan for hu­man test­ing. And there was an ear­ly stake in Ed­i­tas, one of a small group of gene edit­ing up­starts that hope to use CRISPR/Cas9 tech to rev­o­lu­tion­ize med­i­cine—years from now. One of GV’s biggest in­vest­ments is in the Big Da­ta out­fit Flat­iron as well as Foun­da­tion Med­i­cine, which is us­ing emerg­ing mol­e­c­u­lar in­for­ma­tion to guide treat­ment.

Yesh­want likes to play in the messy, wreck-filled in­ter­sec­tions of health­care that need the most help, like the point of con­tact be­tween pay­ers and pa­tients.

“We try to ig­nore dis­tinc­tions,” says Yesh­want, “and start to think of the big ar­eas that need to be worked on.”

Longevi­ty fig­ures promi­nent­ly in its think­ing. In­evitably, that turns to com­ments on dis­rupt­ing no­tions about life span and at­ten­tion-grab­bing head­lines built on liv­ing hun­dreds of years. But that can be a dis­trac­tion as well. GV may be think­ing of the longterm, but its com­pa­nies are al­so mak­ing prac­ti­cal ad­vances, blue­print­ing clin­i­cal sched­ules and deal­ing with the re­al­i­ties of prod­uct de­vel­op­ment — with­in the cur­rent con­structs of a nor­mal life span. GV is fo­cused on the “un­der­ly­ing mech­a­nisms of ag­ing,” says Yesh­want, like Google start­up Cal­i­co. And they’re fol­low­ing that in­to dif­fer­ent com­pa­nies which are trekking a path that leads to dis­eases which can be ad­dressed by new tech­nol­o­gy.

It’s a dif­fer­ent way of look­ing at drug de­vel­op­ment from a ven­ture group that prides it­self in em­brac­ing dif­fer­ent ways of think­ing.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Tim Pearson, Carrick Therapeutics CEO

Pfiz­er backs $60M in­fu­sion in­to Car­rick, teams up on breast can­cer treat­ment

In a big week for Carrick Therapeutics, the company announced $60 million in funding for its lead breast cancer drug and development of a second program, as well as a collaboration with Pfizer for combo development.

The $35 million from Pfizer comes with an agreement under which Pfizer will support Carrick’s Phase II study of samuraciclib in combination with Pfizer’s Faslodex for advanced breast cancer. Along with the investment, Adam Schayowitz, vice president and development head of breast cancer, colorectal cancer and melanoma at Pfizer global product development, will join Carrick’s scientific advisory board.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Thomas Gad, Y-mAbs Therapeutics founder and interim CEO

FDA re­jects Y-mAbs’ neu­rob­las­toma drug af­ter tak­ing is­sue with clin­i­cal tri­al de­sign

Uncertainty about clinical trial evidence has led the FDA to hand down a complete response letter for Y-mAbs’ neuroblastoma drug, casting a cloud on the future of a candidate that had gone through a long development journey in a rare pediatric cancer.

Y-mAbs said it’s disappointed “but not surprised” given that the agency’s oncology drug advisory committee had voted 16-0 against its drug’s approval a few weeks ago.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Philip Tagari switch­es Am­gen's dis­cov­ery lab for in­sitro's ma­chine learn­ing tools; CEO Joaquin Du­a­to to chair J&J's board

In February, Philip Tagari will take a few days of retirement and then immediately return to industry. He won’t be leading the therapeutics discovery unit for a large biopharma, though.

He’ll trade in his Amgen hat for chief scientist at a machine learning startup that has reeled in hundreds of millions in capital to lay the groundwork for a much-hyped new model of drug discovery that aims to speed up the time to new clinical assets.

Raul Rodriguez, Rigel Pharma CEO

Rigel Phar­ma scores FDA ap­proval for leukemia, kick­ing off show­down with Servi­er in IDH1

When Rigel Pharma bought olutasidenib from Forma Therapeutics, it acquired a drug that already secured a PDUFA date at the FDA — for February 2023. But regulators are ready to give their OK sooner than that.

The FDA has approved the IDH1 inhibitor as a treatment for adult patients with relapsed or refractory acute myeloid leukemia who have a susceptible IDH-1 (isocitrate dehydrogenase-1) mutation as detected by an FDA-greenlit test. Rigel will market it as Rezlidhia.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and Am­gen are bring­ing cash to cov­er the ta­ble stakes for the Hori­zon M&A game

With the market cap on Horizon Therapeutics $HZNP pushed up to the $23 billion mark today, one of the Big Pharmas in the hunt for a major league buyout deal signaled it’s playing the M&A game with cash.

Paris-based Sanofi, where CEO Paul Hudson has been largely focused on some risky biotech acquisitions to win some respect for its future pipeline prospects, issued a statement early Friday — complying with Rule 2.12 of the Irish takeover rules — making clear that while the certainty or size of an offer can’t be determined, any offer “will be solely in cash.” And Amgen CEO Robert Bradway came right in behind him, filing a statement on the London Stock Exchange overnight that any offer they may make will “likely” be in cash as well.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Illustration: Assistant Editor Kathy Wong for Endpoints News

As mon­ey pours in­to dig­i­tal ther­a­peu­tics, in­sur­ance cov­er­age crawls



Talk therapy didn’t help Lily with attention deficit hyperactivity disorder, or ADHD. But a video game did.

As the 10-year-old zooms through icy waters and targets flying creatures on the snow-capped planet Frigidus, she builds attention skills, thanks to Akili Interactive Labs’ video game EndeavorRx. She’s now less anxious and scattered, allowing her to stay on a low dose of ADHD medication, according to her mom Violet Vu.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Eli Lil­ly’s Alzheimer’s drug clears more amy­loid ear­ly than Aduhelm in first-ever head-to-head. Will it mat­ter?

Ahead of the FDA’s decision on Eli Lilly’s Alzheimer’s drug donanemab in February, the Big Pharma is dropping a first cut of data from one of the more interesting trials — but less important in a regulatory sense — at an Alzheimer’s conference in San Francisco.

In the unblinded 148-person study, Eli Lilly pitted its drug against Aduhelm, Biogen’s drug that won FDA approval but lost Medicare coverage outside of clinical trials. Notably, the study didn’t look at clinical outcomes, but rather the clearance of amyloid, a protein whose buildup is associated with Alzheimer’s disease, in the brain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Lynn Baxter, Viiv Healthcare's head of North America

Vi­iV dri­ves new cor­po­rate coali­tion in­clud­ing Uber, Tin­der and Wal­mart, aimed at end­ing HIV

ViiV Healthcare is pulling together an eclectic coalition of consumer businesses in a new White House-endorsed effort to end HIV by the end of the decade.

The new US Business Action to End HIV includes pharma and health companies — Gilead Sciences, CVS Health and Walgreens — but extends to a wide range of consumer companies that includes Tinder, Uber and Walmart.

ViiV is the catalyst for the group, plunking down more than half a million dollars in seed money and taking on ringmaster duties for launch today on World AIDS Day, but co-creator Health Action Alliance will organize joint activities going forward. ViiV and the alliance want and expect more companies to not only join the effort, but also pitch in funding.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.